Date  |
|
| Jan 10, 2020 |
CEL-SCI to Participate in Upcoming Investor Conferences |
| Jan 7, 2020 |
CEL-SCI Announces Full Exercise of Over-allotment Option by Aegis Capital Corp. |
| Dec 27, 2019 |
CEL-SCI Announces the Closing of Its $5.5 Million Underwritten Offering |
| Dec 24, 2019 |
CEL-SCI Prices $5.5 Million Underwritten Public Offering of Common Stock |
| Dec 23, 2019 |
CEL-SCI Announces Proposed Underwritten Public Offering of Common Stock |
| Dec 16, 2019 |
CEL-SCI Reports Fiscal 2019 Financial Results and Clinical & Corporate Developments |
| Dec 6, 2019 |
CEL-SCI Corporation to Present at The LD Micro Main Event (XII) |
| Oct 29, 2019 |
CEL-SCI Corporation to Present at Dawson James Securities 5th Annual Small Cap Growth Conference |
| Oct 24, 2019 |
CEL-SCI Corporation Issues Letter to Shareholders |
| Oct 15, 2019 |
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study |